(Q34599632)

3 August 2017

1 reference

title

Caspofungin: an echinocandin antifungal agent (English)

1 reference

3 August 2017

Elizabeth A Stone

1

1 reference

PubMed ID

11952021

3 August 2017

Horatio B Fung

series ordinal

2

1 reference

PubMed ID

11952021

3 August 2017

Harold L Kirschenbaum

series ordinal

3

1 reference

3 August 2017

1 March 2002

1 reference

3 August 2017

Clinical Therapeutics

1 reference

3 August 2017

24

1 reference

3 August 2017

3

1 reference

3 August 2017

351-77; discussion 329

1 reference

Emerging and reemerging microbial threats. Nosocomial fungal infections

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

The fungal cell wall as a drug target

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Investigational antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Compounds active against cell walls of medically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Treatment of histoplasmosis with MK-991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Lipopeptide inhibitors of fungal glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Quality control limits for broth microdilution susceptibility tests of ten antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

1 reference

7 January 2021

The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Treatment of murine disseminated candidiasis with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Treatment of murine Candida krusei or Candida glabrata infection with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985039-1

7 January 2021

10.1016/S0149-2918(02)85039-1

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11952021